• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Tandem Diabetes Care Inc.

    11/21/24 11:22:52 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care
    Get the next $TNDM alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001238913
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    TANDEM DIABETES CARE INC
    SEC File Number
    001-36189
    Address of Issuer
    12400 HIGH BLUFF DRIVE
    San Diego
    CALIFORNIA
    92130
    Phone
    858-366-6900
    Name of Person for Whose Account the Securities are To Be Sold
    BLICKENSTAFF KIM D
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Board of Directors, Chair Emeritus

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    common
    Cowen Execution Servioces, LLC
    1633 Broadway 48th Floor
    New York � NY � 10019
    30000900000.0015957711/21/2024
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common08/18/2020PurchaseTandem Diabetes Care IncCheckbox not checked702008/18/2020cash
    Common05/17/2022PurchaseTandem Diabetes Care, IncCheckbox not checked280005/17/2022cash
    Common11/10/2020PurchaseTandem Diabetes Care IncCheckbox not checked604811/10/2020cash
    Common08/11/2020PurchaseTandem Diabetes Care, IncCheckbox not checked1413208/11/2020cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Kim Blickenstaff
    12400 High Bluff Drive
    San Diego � CA � 92130-3077
    common11/20/202410000300000.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    11/21/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /S/ Kim D Blickenstaff

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $TNDM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TNDM

    DatePrice TargetRatingAnalyst
    1/27/2026$25.00Buy
    TD Cowen
    12/16/2025$30.00Neutral → Outperform
    Robert W. Baird
    10/21/2025$15.00Hold
    Stifel
    9/8/2025$22.00Outperform
    Oppenheimer
    8/12/2025$10.35Sell → Neutral
    Citigroup
    8/7/2025$14.00Overweight → Neutral
    Piper Sandler
    7/9/2025$14.00Neutral → Sell
    Citigroup
    6/16/2025$24.00Hold
    Truist
    More analyst ratings

    $TNDM
    SEC Filings

    View All

    Tandem Diabetes Care Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)

    12/30/25 4:29:52 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Tandem Diabetes Care Inc.

    SCHEDULE 13G - TANDEM DIABETES CARE INC (0001438133) (Subject)

    11/13/25 9:01:10 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)

    11/12/25 9:02:09 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tandem Diabetes Care Announces Upcoming Conference Presentations

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences: Citi's 2026 Unplugged MedTech and Life Sciences Access Day on Thursday, February 26, 2026 at 1:45pm Eastern Time (10:45am Pacific Time), TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026 at 9:10am Eastern Time (6:10am Pacific Time), and Oppenheimer 36th Annual Healthcare MedTech & Services Conference on Wednesday, March 18, 2026 at 1:20pm Eastern Time (10:20am Pacific Time). The presentations will be webcast live, and an archive recording will be available f

    2/12/26 4:05:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2025 results after the financial markets close on Thursday, February 19, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its fourth quarter and full year 2025 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.

    1/8/26 4:05:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    The End of Shots? 5 Biotech Stocks Rethinking Diabetes

    Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Dec. 31, 2025 /PRNewswire/ -- USA News Group News Commentary – Recent clinical trials achieving 83% insulin independence rates have ignited a dramatic shift in metabolic disease investment[1], with late-2025 M&A activity reaching record valuations as major pharmaceutical companies race to secure curative platforms over symptom-management franchises[2]. This pivot toward functional cures rather than chronic insulin dependence is defining the strategic roadmaps of Avant Technologies, Inc. (OTCQB:AVAI), Novo Nordisk A/S (NYSE:NVO), Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN), Viking Therapeutics, Inc. (NASDAQ:VKTX), and Tandem Diabetes C

    12/31/25 8:07:00 AM ET
    $ELDN
    $NVO
    $TNDM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $TNDM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Sheridan John F bought $102,318 worth of shares (10,000 units at $10.23), increasing direct ownership by 10% to 106,327 units (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    8/11/25 6:15:44 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    EVP & CHIEF FINANCIAL OFFICER Vosseller Leigh bought $149,404 worth of shares (13,720 units at $10.89) (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    8/11/25 5:18:51 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    EVP & Chief Operating Officer Kyrillos Jean-Claude bought $190,966 worth of shares (10,538 units at $18.12) (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    3/11/25 6:06:01 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen resumed coverage on Tandem Diabetes Care with a new price target

    TD Cowen resumed coverage of Tandem Diabetes Care with a rating of Buy and set a new price target of $25.00

    1/27/26 8:50:26 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Tandem Diabetes Care from Neutral to Outperform and set a new price target of $30.00

    12/16/25 8:56:07 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Stifel resumed coverage on Tandem Diabetes Care with a new price target

    Stifel resumed coverage of Tandem Diabetes Care with a rating of Hold and set a new price target of $15.00

    10/21/25 7:22:24 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $TNDM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    February 28, 2025 - FDA Roundup: February 28, 2025

    For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

    2/28/25 5:00:47 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    November 7, 2023 - FDA Roundup: November 7, 2023

    For Immediate Release: November 07, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA issued a Safety Communication warning consumers, health care providers, and health care facilities not to use recalled saline (0.9% sodium chloride) and sterile water medical products manufactured by Nurse Assist, LLC. On November 6, Nurse

    11/7/23 3:38:18 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    EVP & Chief Operating Officer Kyrillos Jean-Claude converted options into 3,636 shares and covered exercise/tax liability with 2,118 shares, increasing direct ownership by 7% to 24,062 units (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    1/20/26 4:09:55 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    EVP & CHIEF COMMERCIAL OFFICER Novara Mark David covered exercise/tax liability with 3,843 shares and converted options into 7,415 shares, increasing direct ownership by 11% to 35,956 units (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    12/17/25 4:02:14 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Chief Technology Officer Carpenter Rick covered exercise/tax liability with 207 shares and converted options into 406 shares, increasing direct ownership by 0.83% to 24,252 units (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    12/17/25 4:01:39 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    Leadership Updates

    Live Leadership Updates

    View All

    Tandem Diabetes Care Announces Appointment of Sandra Beaver to Board of Directors

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Sandra Beaver to its board of directors effective November 7, 2025. Ms. Beaver joins the board as an independent director and will serve on the board's Audit Committee and Cybersecurity and Data Oversight Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112460451/en/Sandra Beaver joins Tandem Diabetes Care Board of Directors. "We welcome Sandra to our Board of Directors at this pivotal stage in Tandem's evolution," said John Sheridan, president and CEO. "Sandra is a dynamic finance

    11/12/25 9:00:00 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude "JC" Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620151195/en/Jean-Claude "JC" Kyrillos (Photo: Business Wire) "JC brings deep experience in healthcare and a great balance of technical, operational, and leadership skills from multipl

    6/20/24 9:00:00 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care, Inc investors: Please contact the Portnoy Law Firm to recover your losses; November 2, 2023 deadline

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ:TNDM) investors that a lawsuit filed on behalf of investors that purchased Tandem securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio

    11/7/23 3:47:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    Financials

    Live finance-specific insights

    View All

    Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2025 results after the financial markets close on Thursday, February 19, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its fourth quarter and full year 2025 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.

    1/8/26 4:05:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care Announces Third Quarter 2025 Financial Results

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2025 and reaffirmed full year 2025 guidance. Third Quarter 2025 and Recent Highlights Achieved record third quarter sales both in the United States (U.S.) and internationally Demonstrated year-over-year and sequential gross margin improvement Progressed multi-channel initiative by: Increasing pharmacy benefit coverage for Tandem Mobi to more than 40% of U.S. lives Introducing t:slim X2 supplies through a pharmacy benefit Received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for extend

    11/6/25 4:05:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care to Announce Third Quarter 2025 Financial Results on November 6, 2025

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2025 results after the financial markets close on Thursday, November 6, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BIc60

    10/2/25 4:05:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

    SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

    11/14/24 4:15:44 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

    SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

    9/9/24 10:40:31 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Tandem Diabetes Care Inc.

    SC 13G - TANDEM DIABETES CARE INC (0001438133) (Subject)

    2/14/24 7:37:31 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care